Match!
Jing Jing Li
Auckland City Hospital
9Publications
7H-index
1,062Citations
Publications 9
Newest
#1Anthony HarrisH-Index: 43
#2Jing Jing LiH-Index: 7
Last.Karen Kah Leng YongH-Index: 2
view all 3 authors...
Objective Deciding on public funding for pharmaceuticals on the basis of value for money is now widespread. We suggest that evidence-based assessment of value has restricted the availability of medicines in Australia in a way that reflects the relative bargaining power of government and the pharmaceutical industry. We propose a simple informal game-theoretic model of bargaining between the funding agency and industry and test its predictions using a logistic multiple regression model of past fun...
3 CitationsSource
#1David W. Johnson (UQ: University of Queensland)H-Index: 114
#2Muh Geot Wong (USYD: University of Sydney)H-Index: 15
Last.Carol A. Pollock (RNSH: Royal North Shore Hospital)H-Index: 51
view all 16 authors...
Background: Since the mid-1990s, early dialysis initiation has dramatically increased in many countries. The Initiating Dialysis Early and Late (IDEAL) study demonstrated that, compared with late initiation, planned early initiation of dialysis was associated with comparable clinical outcomes and increased health care costs. Because residual renal function is a key determinant of outcome and is better preserved with peritoneal dialysis (PD), the present pre-specified subgroup analysis of the IDE...
21 CitationsSource
#1Duncan Mortimer (Monash University)H-Index: 16
#2Jing Jing Li (Monash University)H-Index: 7
Last.Anthony Harris (Monash University)H-Index: 43
view all 4 authors...
Funding contingent upon evidence development (FED) has recently been the subject of some considerable debate in the literature but relatively little has been made of its economic impact. We argue that FED has the potential to shorten the lag between innovation and access but may also (i) crowd-out more valuable interventions in situations in which there is a fixed dedicated budget; or (ii) lead to a de facto increase in the funding threshold and increased expenditure growth in situations in whic...
2 CitationsSource
#1Anthony Harris (Monash University, Clayton campus)H-Index: 43
#2Bruce A. Cooper (RNSH: Royal North Shore Hospital)H-Index: 51
Last.David C.H. Harris (USYD: University of Sydney)H-Index: 46
view all 16 authors...
Background Planned early initiation of dialysis therapy based on estimated kidney function does not influence mortality and major comorbid conditions, but amelioration of symptoms may improve quality of life and decrease costs. Study Design Patients with progressive chronic kidney disease and a Cockcroft-Gault estimated glomerular filtration rate of 10-15 mL/min/1.73 m 2 were randomly assigned to start dialysis therapy at a glomerular filtration rate of either 10-14 (early start) or 5-7 mL/min/1...
80 CitationsSource
#1John F. Collins (Auckland City Hospital)H-Index: 16
#2Bruce A. Cooper (Auckland City Hospital)H-Index: 51
Last.Carol A. Pollock (Auckland City Hospital)H-Index: 51
view all 15 authors...
Background : In clinical practice there is considerable variation in the timing of initiation of dialysis. The IDEAL trial (Initiating Dialysis Early and Late study) showed that plan
13 CitationsSource
#1Bruce A. Cooper (USYD: University of Sydney)H-Index: 51
#2Pauline BranleyH-Index: 11
Last.Carol A. Pollock (USYD: University of Sydney)H-Index: 51
view all 15 authors...
BACKGROUND In clinical practice, there is considerable variation in the timing of the initiation of maintenance dialysis for patients with stage V chronic kidney disease, with a worldwide trend toward early initiation. In this study, conducted at 32 centers in Australia and New Zealand, we examined whether the timing of the initiation of maintenance dialysis influenced survival among patients with chronic kidney disease. METHODS We randomly assigned patients 18 years of age or older with progres...
534 CitationsSource
#1Fiona Clement (U of C: University of Calgary)H-Index: 25
#2Anthony HarrisH-Index: 43
Last.Braden J. Manns (U of C: University of Calgary)H-Index: 70
view all 6 authors...
Context National public insurance for drugs is often based on evidence of comparative effectiveness and cost-effectiveness. This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been at the forefront of evidence-based coverage internationally. Objectives To describe how clinical and cost-effectiveness evidence is used in coverage decisions both within and across jurisdictions and to identify common issues in the process of evidence...
243 CitationsSource
#1Fiona ClementH-Index: 25
#2Anthony HarrisH-Index: 43
Last.Braden J. MannsH-Index: 70
view all 6 authors...
Context National public insurance for drugs is often based on evidence of comparative effectiveness and cost-effectiveness. This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been at the forefront of evidence-based coverage internationally.
15 Citations
#1Anthony HarrisH-Index: 43
#2Suzanne Hill (University of Newcastle)H-Index: 31
Last.Emily Walkom (University of Newcastle)H-Index: 9
view all 5 authors...
Objective . To analyze the relative influence of factors in decisions for public insurance coverage of new drugs in Australia.Data Sources. Evidence presented at meetings of the Australian Pharmaceutical Benefits Advisory Committee (PBAC) that makes recommendations on coverage of drugs under Pharmaceutical Benefits Scheme.Study Selection. All major submissions to the PBAC between February 1994 and December 2004 (n = 858) if one of the outcomes measured was life year gained (n=138) or quality-adj...
151 CitationsSource
1